Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04265534
Title KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Calithera Biosciences, Inc
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST